"
Team:Wageningen UR/Flux balance analysis
From 2013.igem.org
(Difference between revisions)
Karrenbelt (Talk | contribs) |
Karrenbelt (Talk | contribs) |
||
| Line 20: | Line 20: | ||
| - | + | </div> | |
| + | </div> | ||
| + | </html> | ||
<!--- Footer Template ---> | <!--- Footer Template ---> | ||
{{:Team:Wageningen_UR/Templates/Page Footer}} | {{:Team:Wageningen_UR/Templates/Page Footer}} | ||
Revision as of 09:53, 10 September 2013
- Safety introduction
- General safety
- Fungi-related safety
- Biosafety Regulation
- Safety Improvement Suggestions
- Safety of the Application
Metabolic modeling
Metabolic modeling
of lovastatin biosynthesis in Aspergilli
Introduction
As a proof of concept lovastatin has been chosen and its production in A. niger will be modeled. To develop and investigate mathematical models of metabolic processes is one of the primary challenges in systems biology. To investigate the potential of lovastatin production, the current metabolic model of A. nigerhas to be expanded. The COBRA toolbox facilitates easy input of the metabolic model in SBML to perform these calculations in MATLAB. Once the model has been expanded flux balance analysis allows for a genome-scale approach. OptKnock can be used to determine which gene knockouts should increase the metabolic flux towards lovastatin.
